Company Profile

Profile last edited on: 3/17/2023      CAGE: 8E3V3      UEI: DPEMWHCURCR5

Business Identifier: Oligonucleotide therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

360 Huntington Avenue
Boston, MA 02115
   (617) 373-7089
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

A spinout company from the Zhang group with close connection to Northeastern University, the driving these of pacDNA LLC is greatly to expand on the areas of disease for which an oligonucleotide-based therapy can be developed. The firm's proprietary delivery technology - designated the Brushield™ - is structured to boost biodistribution in otherwise hard-to-deliver sites, reducing potential side effects, and generating lasting potency - making possible the development of multiple therapies for diseases that are currently out of reach.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $1,485,054
Project Title: Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

Key People / Management

  Yang Fang -- Scientist

  Ke Zhang

Company News

There are no news available.